evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

294 questions · 295 findings · 16 reviews · Schizophrenia

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 79 · 26.8%GRADE not reported 32 · 10.8%Very low 99 · 33.6%Low 55 · 18.6%Moderate 17 · 5.8%High 13 · 4.4%

Droperidol vs haloperidol

Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) · acute psychosis

Droperidol leads to lower global state: use of additional medication ‐ by 60 minutes after… compared with haloperidol (high certainty).

1 finding from 1 review

CHLORPROMAZINE vs haloperidol

Global outcome: Number of additional injections ‐ 2‐4 injections · patients with psychosis‐induced aggression or agitation

It is very uncertain whether CHLORPROMAZINE changes global outcome: Number of additional injections ‐ 2‐4 injections compared with HALOPERIDOL (very low certainty).

1 finding from 1 review

CHLORPROMAZINE vs haloperidol

Global outcome: Number of additional injections ‐ 5 or more · patients with psychosis‐induced aggression or agitation

It is very uncertain whether CHLORPROMAZINE changes global outcome: Number of additional injections ‐ 5 or more compared with HALOPERIDOL (very low certainty).

1 finding from 1 review

CHLORPROMAZINE vs haloperidol

Adverse effects ‐ cardiovascular ‐ hypotension · patients with psychosis‐induced aggression or agitation

It is very uncertain whether CHLORPROMAZINE changes adverse effects ‐ cardiovascular ‐ hypotension compared with HALOPERIDOL (very low certainty).

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Leaving the study early (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. standard higher dose (>… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Global state: No clinically significant response (as defined by the original studies) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Global state: 1. No clinically significant response in global state (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).

1 finding from 1 review